The Accelerating Clinical Trials in the EU (ACT EU) initiative has published a draft guidance document outlining how clinical trials should be conducted during public health emergencies. This guidance aims to streamline the clinical trial process, ensuring that critical research can continue even in times of crisis, thereby enhancing the EU’s capacity to respond to health emergencies effectively.
In light of recent global health challenges, including the COVID-19 pandemic, regulatory bodies recognize the urgent need for adaptive trial designs and flexible regulatory frameworks. The new guidance encourages the incorporation of innovative methodologies, such as remote monitoring and decentralized trial approaches, which can facilitate patient participation and data collection while minimizing risks associated with traditional trial settings.
The implications of this guidance are significant for pharma B2B professionals involved in regulatory affairs, quality assurance, and clinical development. By embracing these recommendations, stakeholders can expedite the delivery of vital therapies and vaccines, ultimately improving public health outcomes during emergencies.
Use the database as your supply chain compass →
